PL3411021T3 - Nowe zastosowanie kombinacji sakubitrylu i walsartanu - Google Patents

Nowe zastosowanie kombinacji sakubitrylu i walsartanu

Info

Publication number
PL3411021T3
PL3411021T3 PL17703477.4T PL17703477T PL3411021T3 PL 3411021 T3 PL3411021 T3 PL 3411021T3 PL 17703477 T PL17703477 T PL 17703477T PL 3411021 T3 PL3411021 T3 PL 3411021T3
Authority
PL
Poland
Prior art keywords
sacubitril
new application
valsartan
combination
valsartan combination
Prior art date
Application number
PL17703477.4T
Other languages
English (en)
Inventor
Fabian CHEN
Surya Prakash AYALASOMAYAJULA
Christopher Bush
Masha BERKHIN
Gesine Winzenburg
Bernd TRUEBY
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3411021(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3411021T3 publication Critical patent/PL3411021T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17703477.4T 2016-02-03 2017-02-02 Nowe zastosowanie kombinacji sakubitrylu i walsartanu PL3411021T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16154153 2016-02-03
US201662293005P 2016-02-09 2016-02-09
US201662393163P 2016-09-12 2016-09-12
PCT/IB2017/050573 WO2017134600A1 (en) 2016-02-03 2017-02-02 New use of a combination of sacubitril and valsartan

Publications (1)

Publication Number Publication Date
PL3411021T3 true PL3411021T3 (pl) 2025-09-08

Family

ID=55299378

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17703477.4T PL3411021T3 (pl) 2016-02-03 2017-02-02 Nowe zastosowanie kombinacji sakubitrylu i walsartanu

Country Status (19)

Country Link
US (3) US20190054069A1 (pl)
EP (3) EP3411021B1 (pl)
JP (4) JP7156945B2 (pl)
KR (1) KR102805176B1 (pl)
CN (1) CN108601741B (pl)
AU (2) AU2017215530B2 (pl)
CA (1) CA3010778C (pl)
DK (1) DK3411021T3 (pl)
ES (1) ES3036922T3 (pl)
FI (1) FI3411021T3 (pl)
HR (1) HRP20250913T1 (pl)
HU (1) HUE072182T2 (pl)
IL (1) IL260955A (pl)
LT (1) LT3411021T (pl)
PL (1) PL3411021T3 (pl)
PT (1) PT3411021T (pl)
RS (1) RS67127B1 (pl)
SI (1) SI3411021T1 (pl)
WO (2) WO2017134600A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250913T1 (hr) 2016-02-03 2025-09-26 Novartis Ag Nova upotreba kombinacije sakubitrila i valsartana
US20200276129A1 (en) * 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
US20210177803A1 (en) * 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
KR102545274B1 (ko) * 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
WO2021172960A1 (ko) * 2020-02-26 2021-09-02 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
KR20220091767A (ko) * 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
WO2022165339A1 (en) * 2021-01-31 2022-08-04 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
TWI823471B (zh) * 2021-07-12 2023-11-21 大陸商上海雲晟研新生物科技有限公司 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
CN116687921A (zh) * 2023-06-14 2023-09-05 宁波大学 沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
EP1416922A1 (en) * 2001-07-16 2004-05-12 AstraZeneca AB Pharmaceutical formulation comprising a proton pump inhibitor and antacids
PT1467728E (pt) 2002-01-17 2007-11-14 Novartis Ag Composições farmacêuticas compreendendo valsartan e inibidores da nep
US7638638B2 (en) * 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN101848700A (zh) 2007-11-06 2010-09-29 诺瓦提斯公司 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物
CN102300558A (zh) * 2009-01-28 2011-12-28 诺瓦提斯公司 有机化合物的盖伦制剂
PH12013500231A1 (en) 2010-08-24 2017-08-09 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
SI2887961T1 (sl) 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
RS65037B1 (sr) 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
HRP20250913T1 (hr) 2016-02-03 2025-09-26 Novartis Ag Nova upotreba kombinacije sakubitrila i valsartana

Also Published As

Publication number Publication date
US20250325518A1 (en) 2025-10-23
LT3411021T (lt) 2025-08-25
AU2017215530A1 (en) 2018-07-26
CN108601741A (zh) 2018-09-28
AU2017215530B2 (en) 2019-09-12
WO2017134600A1 (en) 2017-08-10
EP3411018A1 (en) 2018-12-12
EP3411021B1 (en) 2025-05-14
US20240207227A1 (en) 2024-06-27
PT3411021T (pt) 2025-08-06
HUE072182T2 (hu) 2025-10-28
EP4609912A2 (en) 2025-09-03
ES3036922T3 (en) 2025-09-25
FI3411021T3 (fi) 2025-07-31
US20190054069A1 (en) 2019-02-21
RS67127B1 (sr) 2025-09-30
JP2023021991A (ja) 2023-02-14
CA3010778A1 (en) 2017-08-10
KR20180103940A (ko) 2018-09-19
KR102805176B1 (ko) 2025-05-12
JP2019504094A (ja) 2019-02-14
HRP20250913T1 (hr) 2025-09-26
AU2019280026B2 (en) 2021-09-02
WO2017134597A1 (en) 2017-08-10
EP4609912A3 (en) 2025-11-12
EP3411021A1 (en) 2018-12-12
JP2024160386A (ja) 2024-11-13
SI3411021T1 (sl) 2025-09-30
JP6810152B2 (ja) 2021-01-06
JP2019504096A (ja) 2019-02-14
IL260955A (en) 2018-09-20
CN108601741B (zh) 2022-05-24
JP7156945B2 (ja) 2022-10-19
DK3411021T3 (da) 2025-08-18
CA3010778C (en) 2024-02-27
AU2019280026A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL293377B1 (en) Hsd17b13 variants and uses thereof
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
PT3548033T (pt) Compostos e respectivos métodos de utilização
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
IL254039A0 (en) Anti-pvrig antibodies and methods of use
IL280863A (en) Autotaxin inhibitors and uses thereof
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
IL258768A (en) Glycan-interacting compounds and methods of use
IL263680A (en) Combination therapies
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
IL252026B (en) Humanized anti-complement factor c1q antibodies and uses thereof
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
IL251970B (en) Anti-cd79b antibodies and methods of use
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
HUE052373T2 (hu) Szubsztituált krománok és alkalmazási eljárások
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
MA41997A (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
IL256531B (en) Oxysterols and methods of use thereof
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
BR112016020889A2 (pt) variantes de hppd e métodos de uso
IL250173B (en) Actuation mechanism and associated methods
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder